Table 3.
Subgroup analysis of tumour response according to whether or not they received antiviral therapy, n (%)
|
|
Antiviral therapy (no), n = 25
|
Antiviral therapy (yes), n = 95
|
||||
|
HBV-DNA (HBV > 2000), n = 8
|
HBV-DNA (HBV ≤ 2000), n = 18
|
P value
|
HBV-DNA (HBV > 2000), n = 46
|
HBV-DNA (HBV ≤ 2000), n = 48
|
P value
|
|
| PR | 2 (29) | 3 (17) | 0.597 | 15 (32) | 10 (21) | 0.220 |
| SD | 3 (43) | 11 (61) | 0.656 | 18 (38) | 24 (50) | 0.251 |
| PD | 2 (29) | 4 (22) | > 0.999 | 14 (30) | 14 (29) | 0.947 |
| ORR | 2 (29) | 3 (17) | 0.597 | 16 (34) | 10 (21) | 0.149 |
| DCR | 5 (71) | 14 (78) | > 0.999 | 35 (74) | 34 (71) | 0.691 |
| ORR (whole) | 5 (20) | - | 26 (27) | 0.454 | ||
| DCR (whole) | 6 (24) | - | 26 (27) | 0.735 | ||
Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; PR: Partial responds; SD: Stable disease; PD: Progression disease; ORR: Objective responds rates; DCR: Disease control rates.